Background: Functional polymorphisms in the receptor for advanced glycation end-products (RAGE) gene have been implicated in several vascular diseases. However, to date, no study investigated the association of RAGE polymorphisms with heart failure (HF). Objective: In this study we tested the hypothesis that the 63-bp insertion/deletion, the −374T > A (rs1800624) and the −429T> C (rs1800625) polymorphisms in the RAGE gene might be associated with susceptibility to HF and could predict all-cause mortality in Brazilian outpatients with left ventricular systolic dysfunction. Methods: A total of 273 consecutive HF patients (196 Caucasian-and 77 African-Brazilians) and 334 healthy blood donors (260 Caucasian-and 74 African-Brazilians) were enrolled in a tertiary care university hospital. Genotyping of RAGE polymorphisms was done by polymerase chain reaction (PCR) or PCR followed by enzyme restriction analysis. Results: The allele, genotype and haplotype frequencies of −374T > A and −429T > C polymorphisms were not significantly different between HF patients and healthy blood donors in both ethnic groups. However, among African-Brazilians, the frequency of carriership of the del allele was lower in HF patients than in blood donors (2.6% vs 12.2%, respectively, p = 0.008). Patients were followed-up for a median of 38 months and the survival analysis did not reveal a consistent association between RAGE polymorphisms and all-cause death in both ethnic groups. Conclusion: The − 374T> A and −429T > C polymorphisms in the RAGE gene were not associated with the susceptibility and prognosis of HF. Notwithstanding, the 63-bp ins/del polymorphism might be involved in the susceptibility to HF in African-Brazilians.
a b s t r a c t a r t i c l e i n f o
Introduction
Heart failure (HF) is a clinical syndrome that represents the endstage of several heart diseases and remains a major cause of morbidity and mortality worldwide. Despite recent advances in its medical treatment, mortality rates due to HF remain elevated (Davis et al., 2000; Roger et al., 2011) . Heart failure is a multifactorial disorder, having clinical, environmental and genetic components. Thus, some common gene variants could increase the risk of developing HF and others could modify disease progression or response to pharmacological therapy (Dorn, 2011) .
The receptor for advanced glycation end-products (RAGE) is a member of the immunoglobulin superfamily of cell surface proteins that binds advanced glycation end-products (AGEs) and other molecules. It is expressed at low levels in most adult tissues under physiological conditions, but is overexpressed in the vessel wall at sites of vascular pathology (Kalea et al., 2009 ). In particular, RAGE levels are higher in diabetic patients and animal models of diabetes than in their non-diabetic counterparts (Kalea et al., 2009; Yan et al., 2009 ). Accumulating experimental evidence has shown that the interaction of AGEs with RAGE leads to activation of intracellular signaling, gene expression, and production of proinflammatory cytokines and free radicals, thus playing a central role in the pathogenesis of vascular and heart disease (Park et al., 2011; Yan et al., 2009 ). sRAGE, the soluble form of RAGE, can be formed by both alternative splicing of the RAGE gene (endogenously secreted RAGE-esRAGE) and proteolytic cleavage of membrane-bound RAGE (cleaved RAGE-cRAGE). The ability of sRAGE to bind RAGE ligands suggests a cytoprotective action against AGEs (Kalea et al., 2009) . Two prospective studies showed that high sRAGE circulating levels were associated with severity of disease and predicted cardiac events in patients with HF, regardless of AGE levels and other known prognostic parameters (Koyama et al., 2008; Raposeiras-Roubín et al., 2011) . Moreover, high sRAGE levels were also associated with ischemic HF (Raposeiras-Roubín et al., 2010) and one study has shown that cRAGE levels are increased while esRAGE levels are decreased in patients with HF as compared to healthy controls (Wang et al., 2011) .
Three polymorphisms described in the promoter of RAGE gene, namely, a 63-bp insertion/deletion spanning from −407 to −345 nucleotides, the −374T>A (rs1800624) and the −429T>C (rs1800625) polymorphisms were shown to have a marked effect on in vitro transcriptional activity. The −429C, −374A and 63-bp del alleles resulted in an increase of gene expression of two-, three-and four-fold, respectively (Hudson et al., 2001a) . Since then, these polymorphisms were studied as potential risk factors involved in the pathogenesis of heart diseases in several populations (Aydoğan et al., 2012; Boiocchi et al., 2011; Falcone et al., 2004 Falcone et al., , 2005 Falcone et al., , 2007 Falcone et al., , 2008 Hudson et al., 2001b; Kirbis et al., 2004; Lu et al., 2008; Peng et al., 2009; Pettersson-Fernholm et al., 2003; Picheth et al., 2007; Poon et al., 2010; Santos et al., 2005; Shim et al., 2007; Yoon et al., 2007) . In particular, the AA genotype of the −374T>A polymorphism was shown to be associated with a reduced risk of cardiovascular disease (coronary heart disease, acute myocardial infarction, peripheral vascular disease) (Pettersson-Fernholm et al., 2003) , coronary artery disease (Falcone et al., 2004) , ischemic heart disease (Santos et al., 2005) , restenosis after coronary stent implantation (Falcone et al., 2007) , acute myocardial infarction (Boiocchi et al., 2011) , adverse cardiac events (Falcone et al., 2008) and with less severe coronary artery disease (Falcone et al., 2005; Picheth et al., 2007) .
Although there are studies evidencing that sRAGE levels levels are predictors of worse prognosis in HF patients (Koyama et al., 2008; Raposeiras-Roubín et al., 2011) and that polymorphisms in the RAGE gene might be associated with development and severity of cardiovascular diseases (Boiocchi et al., 2011; Falcone et al., 2004 Falcone et al., , 2005 Falcone et al., , 2007 Falcone et al., , 2008 Pettersson-Fernholm et al., 2003; Picheth et al., 2007; Santos et al., 2005) , to our knowledge, no study investigated the role of RAGE gene polymorphisms in the pathogenesis of HF. Therefore, in this study we tested the hypothesis that three functional polymorphisms in the RAGE gene promoter, namely, the 63-bp insertion/deletion, − 374T > A and − 429T > C, might be associated with susceptibility to HF and could predict all-cause mortality in Brazilian outpatients with left ventricular systolic dysfunction.
Material and methods

Study population
A total of 273 consecutive HF patients with systolic dysfunction (196 Caucasian-Brazilians and 77 African-Brazilians), diagnosed according to the ACCF/AHA guidelines (Jessup et al., 2009) , were recruited from the Heart Failure and Transplant Outpatient Clinic of a tertiary care university hospital in Porto Alegre, Brazil between July 2003 and November 2007. The inclusion criteria were age ≥18 years and left ventricular ejection fraction b 45%. All patients had HF of idiopathic, ischemic or hypertensive etiology. Patients with HF due to obstructive, hypertrophic or other cardiomyopathies (such as chagasic and alcoholic) were excluded from the study, as well as patients with other serious illnesses or with reduced life expectancy. At baseline, patients underwent a comprehensive clinical and biochemical evaluation consisting of a physical examination, assessment of echocardiographic parameters and laboratory tests. Diabetes was diagnosed according to the American Diabetes Association criteria (American Diabetes Association, 2008) . Demographical, clinical and routine laboratory data were collected from all patients using a structured data form.
We also evaluated a group of 334 presumably healthy controls (260 Caucasian-Brazilians and 74 African-Brazilians) composed by unrelated blood donors enrolled at the Hemotherapy Center of the same hospital at the same period as HF patients. Before blood donation, volunteers who accepted to participate in the protocol underwent a systematic interview to evaluate personal or family history of premature sudden death or cardiovascular diseases, the presence of atherosclerotic risk factors or any overt clinical disease. Those with a history of cardiovascular disease or related symptoms and those with a positive family history of premature sudden death were excluded. No additional laboratory data were collected from blood donors.
The ethnic classification of all subjects was self-reported. The study protocol was approved by the local institutional review board and by the National Agency of Ethics in Research and conforms to the principles outlined in the Declaration of Helsinki. All subjects provided written informed consent before enrollment.
Outcome assessment
The HF patients were followed-up in the outpatient clinic of our institution. Vital status was determined using the last registry assessed in the hospital's electronic database. Telephone contact was attempted for all patients for whom no registry was found in the four months prior to follow-up assessment. Death from any cause was also verified through the State Death Certificate Database.
DNA extraction and genotyping
Genomic DNA was extracted from peripheral blood according to a salting out method as previously described (Lahiri and Nurnberger, 1991) . RAGE genotypes were identified by polymerase chain reaction followed by restriction fragment length polymorphism (PCR-RFLP) analysis, as previously described for the −374T>A and −429T>C polymorphisms (Hudson et al., 2001a) . The amplified products digested by TasI restriction enzyme (−374T>A polymorphism) were electrophoresed on 8% polyacrylamide gels, stained with ethidium bromide and visualized under ultraviolet light. The digested fragments with AluI (−429T>C polymorphism) were separated by electrophoresis on 2% agarose gels containing ethidium bromide and also visualized under ultraviolet light. Both restriction enzymes were purchased from MBI Fermentas (St. Leon-Rot., Germany).
The 63-bp insertion/deletion was detected by PCR using the same primers and conditions as described before for the −374T>A and −429T>C polymorphisms (Hudson et al., 2001a) . The alleles were identified according to the length of bands after separation of PCR fragments in ethidium bromide-stained 2% agarose gels, followed by direct visualization under ultraviolet light. As the −374T>A polymorphism is within the region where the 63-bp deletion occurs, the ins/del heterozygotes cannot be homozygotes or heterozygotes for the −374T>A polymorphism. These subjects can only have the T or the A allele in the −374 nucleotide site, so they were defined as having the T/del or the A/del genotype.
In order to improve genotyping accuracy, samples with known genotypes were used in each run and genotyping was performed by laboratory personnel who were unaware of clinical status of the subjects. The minimal genotyping success rate was 97.4%.
Statistical analysis
Continuous data are reported as mean ± SD, for variables with normal distribution, or as median (interquartile range), for variables with skewed distribution. Categorical variables are reported as absolute numbers and percentages. Kolmogorov-Smirnov test was used to verify the normality of quantitative variables. Continuous variables were compared by the Student t test or Mann-Whitney U test and categorical variables by the chi-square test or Fisher Exact test, as appropriate. Allele frequencies were determined by gene counting and departures from Hardy-Weinberg equilibrium (HWE) were verified using the chi-square test. The chi-square test was also used to compare the allele and genotype frequencies among groups of subjects.
The association of RAGE gene polymorphisms with HF susceptibility was also evaluated by logistic regression analysis with estimates of odds ratios (ORs) and 95% confidence intervals (CI) whenever required to control for confounders. For the analysis of prognosis, Kaplan-Meier survival curves were constructed from the date of entry at the outpatient clinic to the last registry of follow-up or death and compared by the log-rank statistics.
Haplotype frequencies were estimated by a Bayesian method using PHASE program, version 2.1 (Stephens and Scheet, 2005; Stephens et al., 2001) . Carriers of either the T/del or A/del genotypes were excluded from haplotype analysis. We also used the PHASE program to compare the distribution of different RAGE haplotypes between groups of subjects (cases and controls), computing p-values by a case-control permutation test with 1000 random replicates. Moreover, individual haplotypes were compared between cases and controls by Z-score, using PEPI program version 4.0 (Abramson and Gahlinger, 2002) . The linkage disequilibrium between −374T>A and −429T>C polymorphisms was calculated according to the Lewontin formulae (Lewontin, 1988) and expressed in terms of D′.
All statistical analyses were stratified by self-reported ethnicity and were done using SPSS statistical package (version 16.0). In addition to the main analysis considering the group of HF patients as a whole, all data were also analyzed stratifying by diabetes. A p-value b0.05 was considered to be statistically significant.
Among Caucasian-Brazilians, the power to detect an association of − 374T >A and − 429T > C polymorphisms with HF was 94% and 93%, respectively, at a significance level of 0.05 for an OR of 2.0, considering the carriership of the minor alleles as the risk factor. For AfricanBrazilians, our study had a power of 79% and 67% for the −374T>A and −429T>C polymorphisms, respectively, to detect an OR of 2.5, also considering the carriership of the minor alleles as the risk factor. Power calculations were done with PEPI program (Abramson and Gahlinger, 2002) .
Results
Clinical and demographic characteristics
Clinical and demographic characteristics of HF patients are summarized according to self-reported ethnicity (Table 1) . In both groups, HF patients were predominantly middle-aged male, with moderate to severe left ventricular dysfunction and in New York Heart Association class I or II. African-Brazilian HF patients had a higher prevalence of hypertensive etiology, whereas Caucasians had predominantly ischemic etiology. The majority of patients were taking standard pharmacological therapy for HF, including beta-blockers and angiotensin-converting enzyme inhibitors. Most healthy subjects (control group) were male (approximately 70% in both ethnic groups), with a similar mean age (46 ± 12 years and 47± 10 years in Caucasian-and African-Brazilians, respectively), being significantly younger than HF patients (pb 0.001).
Association between RAGE polymorphisms and susceptibility to heart failure
The genotype frequencies were in agreement with those predicted by the Hardy-Weinberg equation for all RAGE polymorphisms in both HF patients and healthy blood donors, except for the 63-bp ins/del polymorphism in African-Brazilian HF patients, for which there was a lower frequency of heterozygotes than expected (expected frequency= 3.9% vs observed frequency=1.3%, p b 0.001). Among healthy blood donors, the genotype and allele frequencies of the 63-bp ins/del polymorphism in Caucasian-Brazilians were significantly different from those of African-Brazilians (pb 0.01) ( Table 2) .
As shown in Table 2 , the frequency of carriers of the del allele was marginally lower in HF patients as compared to blood donors among African-Brazilians (2.6% vs 12.2%, p = 0.051) and the del allele revealed to be associated with HF susceptibility (OR 0.19, 95% CI 0.04-0.92, p = 0.039). Even after controlling for age and gender, the del allele remained as an independent factor associated with a decreased risk of having HF in African-Brazilians (OR 0.16, 95% CI 0.02-0.96, p = 0.046). In relation to the − 374T > A and − 429T > C polymorphisms, there were no statistically significant differences in genotype and allele frequencies between blood donors and HF patients in either Caucasian-or African-Brazilians. These analyses were also carried out assuming three different genetic models for the minor alleles (dominant, recessive and codominant) and no association of these polymorphisms with HF was suggested (data not shown).
Association between RAGE polymorphisms and prognosis of heart failure
Clinical follow-up data were collected for all enrolled HF patients. During a median follow-up of approximately 38 months (range 1-116), 92 patients had died (33.2%), being 64 Caucasian-and 28 African-Brazilians. Fig. 1 depicts the Kaplan-Meier survival curves for all-cause mortality in Caucasian-and African-Brazilians according to the 63-bp ins/del, −374T>A and −429T>C polymorphisms in RAGE gene, respectively. Analyses showed a similar survival profile in both ethnic groups for all-cause death for the −374T>A and −429T>C polymorphisms. Among African-Brazilians, carriers of the del allele had lower event-free survival (log-rank p-value= 0.007).
Association between RAGE haplotypes and heart failure
Next, using a Bayesian method to estimate the frequency of different haplotypes composed of the − 374T >A and − 429T >C polymorphisms, we sought to investigate if a specific haplotype would be associated with HF susceptibility or progression. The − 374T> A and − 429T >C polymorphisms were almost in complete linkage disequilibrium among Caucasian-Brazilians (D′ = − 0.99 in both blood donors and HF patients) and African-Brazilians (D′ = − 0.99 in blood donors and D′ = − 0.98 in HF patients). As can be seen in Table 3 , the − 374T/− 429T haplotype was the most frequent one in all groups of subjects. The haplotype frequencies in HF patients were very similar to those observed in healthy blood donors, in both ethnic groups. We further analyzed mortality outcome in HF patients according to the carriership of at least one minor allele considering the − 374T/− 429T haplotype as the reference. As depicted in Fig. 2 , no association of haplotypes with all-cause mortality was observed in Caucasian-and African-Brazilians.
Association between RAGE polymorphisms and heart failure in diabetic and non-diabetic patients
Taking into account that there may be an interaction between diabetes and RAGE gene polymorphisms on the development and progression of HF, we repeated all analyses stratifying by diabetes (see supplementary material available online). All diabetic patients had type 2 diabetes. Among Caucasian-Brazilians, there was a trend Fig. 1 . Kaplan-Meier survival curves for all-cause mortality in Caucasian-(A to C) and African-Brazilians (D to F) according to the 63-bp ins/del, −374T>A and −429T>C polymorphisms in RAGE gene, respectively. towards a higher frequency of carriership of the del allele (63-bp ins/ del polymorphism) in diabetic HF patients as compared to healthy blood donors (Supplementary Table S1 ). Likewise, the del allele tended to be more frequent among HF patients with diabetes in comparison to healthy blood donors and HF patients without diabetes. On the other hand, among African-Brazilian subjects (Supplementary  Table S2 ), the frequency of carriers of the del allele was lower in HF patients than in healthy blood donors. As shown in Supplementary Table S3, the haplotype frequencies in Caucasian-Brazilian HF patients were similar to those observed in healthy blood donors of the same ethnic group, regardless of the presence of diabetes. However, among African-Brazilians, haplotypes containing either the −374A or −429C allele were more frequent among HF patients without diabetes than in those with diabetes (Supplementary Table S4 ). In fact, carriership of at least one minor allele was found to be associated with diabetes among African-Brazilian HF patients (OR 0.31, 95% CI 0.11-0.89, p = 0.029). However, after controlling for clinical variables that were also associated with diabetes in the univariate analysis (percutaneous transluminal coronary angioplasty/ stent, peripheral vasculopathy, left ventricular end-diastolic volume, diastolic blood pressure, serum triglycerides and potassium levels), the carriership of at least one minor allele did not remain associated with diabetes (OR 0.32, 95% CI 0.04-2.96, p =0.319).
In relation to survival profile for all-cause mortality stratified by diabetes ( Supplementary Figs. S1 to S3 ), the only statistically significant finding was observed for the 63-bp ins/del polymorphism ( Supplementary Fig. S2 ) among non-diabetic African-Brazilians (log-rank p-value = 0.017).
Discussion
In the present study, no association of the −374T>A and −429T>C polymorphisms in RAGE gene with the susceptibility and prognosis of HF was observed in Caucasian-and African-Brazilian outpatients with systolic dysfunction. However, among African-Brazilians, the del allele of the 63-bp ins/del polymorphism was associated with a lower risk of HF and carriers of this allele had a higher mortality rate than homozygotes for the ins allele. Although there is some degree of genetic admixture in Southern Brazilian population, the prevalence of the studied polymorphisms was similar to that previously reported (Hudson et al., 2001a; Kalea et al., 2009; Picheth et al., 2007; Santos et al., 2005; Torres et al., 2012) . Notably, the del allele (63-bp ins/del polymorphism) seems to be more frequent in non-Caucasians than in Caucasians (Hudson et al., 2001a; Poon et al., 2010; Santos et al., 2005; Torres et al., 2012) .
Since the 63-bp ins/del, the − 374T > A and the −429T > C polymorphisms of the promoter region were described as affecting the RAGE gene expression in 2001 (Hudson et al., 2001a) , several studies analyzed their role in the pathogenesis of diverse cardiovascular diseases in both diabetic and non-diabetic patients (Aydoğan et al., 2012; Boiocchi et al., 2011; Falcone et al., 2004 Falcone et al., , 2005 Falcone et al., , 2007 Falcone et al., , 2008 Hudson et al., 2001b; Kirbis et al., 2004; Lu et al., 2008; Peng et al., 2009; Pettersson-Fernholm et al., 2003; Picheth et al., 2007; Poon et al., 2010; Santos et al., 2005; Shim et al., 2007; Yoon et al., 2007) . In most of these studies, the − 374A allele was found to be protective against the development and/or severity of ischemic heart disease, coronary artery disease and acute myocardial infarction, including two previous studies in Brazilians with type 2 diabetes (Picheth et Haplotype frequencies are shown as percentage of a given number (n) of subjects. PHASE program was used to estimate the haplotype frequencies and to compare blood donors vs. HF patients, computing p-values by a case-control permutation test. Individual haplotypes were compared between blood donors and HF patients using Z-score in PEPI program. S.E., standard error. Fig. 2 . Kaplan-Meier survival curves for all-cause mortality in Caucasian-(A) and African-Brazilians (B) according to the number of minor alleles carried.
al. Santos et al., 2005) . However, we failed to demonstrate an association of the − 374T/A polymorphism with the presence of HF itself and with mortality in HF patients. These discrepancies may be related to the heterogeneous clinical and biological profiles of the populations enrolled in the different studies, including the definition of outcomes (composite or only one), exclusion criteria, glucose metabolism status and sample size. In fact, the studies that failed to show a role of the −374T>A polymorphism in heart disease were mainly conducted on subjects of oriental ethnicity. The −429T>C polymorphism has also been studied along with −374T>A; however, no association has been reported with cardiovascular disease (Hudson et al., 2001b; Kirbis et al., 2004; Lu et al., 2008; Pettersson-Fernholm et al., 2003; Poon et al., 2010; Santos et al., 2005; Shim et al., 2007; Yoon et al., 2007) , as also observed in the present study.
In a study on Chinese type 2 diabetic patients with diabetic nephropathy, patients were followed for 8 years for the development of cardiovascular events and survival (Poon et al., 2010) . It was observed that subjects with at least one minor allele of the three RAGE polymorphisms had a lower incidence of ischemic heart disease and HF as compared with those having no minor allele (homozygous for major alleles). In the present study, the frequency of carriership of at least one minor allele was similar in different groups of subjects. However, in line with the findings of Chinese study, the carriership of del allele (63-bp ins/del polymorphism) was less frequent in HF patients as compared to healthy blood donors, which suggests a protective role of this polymorphism for the development of HF.
Moreover, Poon et al. (2010) found that patients with the ins/del genotype had a higher event-free survival rate than homozygotes for the ins allele. In that study, the primary endpoint was a composite one that consisted of cardiovascular death and congestive heart failure, among others. In our study, on the contrary, African-Brazilian carriers of the del allele had a lower survival rate. Nevertheless, the protective role of del allele observed in the Chinese study (Poon et al., 2010) was not independent of other risk factors and in our study there were only two carriers of del allele among African-Brazilian HF patients, one of whom died in the first months of follow-up. Thus, the importance of the 63-bp ins/del polymorphism in the manifestation of clinical events remains unsolved. In addition, none of the polymorphisms studied in Chinese patients had a significant effect on all-cause mortality or cardiovascular mortality (Poon et al., 2010) , as also observed in our study for the −374T>A and −429T>C polymorphisms.
In our study, the genotype frequencies of the 63-bp ins/del polymorphism were not in HWE in African-Brazilian HF patients. Departures from HWE are attributable to population stratification, non-random mating, evolutionary forces and also genotyping errors. Traditionally, genotyping errors are assumed as the most common cause of deviation from HWE (Hosking et al., 2004) . However, some authors state that in association studies, in the presence of a gene-disease association, HWE may be violated in individuals with the disease, because alleles within genotypes that confer greater susceptibility are represented in the sample at disproportionally high rates. So, the violation of HWE in the case group may be due to a real association, while the control group is in equilibrium (Nielsen et al., 1999) . Our results are in agreement with this assumption, since the genotype frequencies were in HWE in African-Brazilian blood donors, and both groups of subjects had identical sample size. It is unlikely that genotyping errors have occurred, because personnel in laboratory were blinded to the characteristics of the subjects. After the preliminary analysis, genotyping of all the samples of African-Brazilian HF patients was repeated, generating the same results. Nevertheless, the results observed in our study regarding the 63-bp ins/ del polymorphism in African-Brazilians should be viewed with caution due to the small sample size (which contributes to low statistical power) and the low frequency of the del allele. These preliminary findings highlight the need of evaluating the 63-bp ins/del polymorphism in other African-derived populations, with appropriate sample size.
It is well described that glycemic status influences the relationship between RAGE polymorphisms and clinical outcomes (Engelen et al., 2010; Falcone et al., 2008; Kucukhuseyin et al., 2009; Picheth et al., 2007) . In a Brazilian study, the − 374AA genotype was associated with decreased severity of coronary artery disease only in the group of patients with type 2 diabetes. Among non-diabetic subjects, this protective effect was not observed (Picheth et al., 2007) . Accordingly, the −374AA genotype was found to be a protective factor for cardiac events in non-diabetic Italians with coronary artery disease (Falcone et al., 2008) . In contrast with these studies, the −374A allele was found to be a risk factor for coronary artery disease in Turkish patients with diabetes (Kucukhuseyin et al., 2009) . Moreover, in two Dutch population-based cohort studies, the −374AA genotype was protectively associated with blood pressure and arterial stiffness in individuals with normal glucose metabolism, whereas in individuals with impaired glucose metabolism or type 2 diabetes, the same genotype was adversely associated with these variables (Engelen et al., 2010) .
In the present study, although not statistically significant, the differences in the frequency of RAGE polymorphisms were found in the comparison between HF patients with type 2 diabetes and healthy blood donors. The significative findings were observed for the 63-bp ins/del polymorphism. The causal mechanism for these contrasting effects is still unknown, but as already suggested (Engelen et al., 2010) , metabolic abnormalities in response to hyperglycemia seem to influence the effects of RAGE polymorphisms. Thus, diabetes is a potential modifier factor that should be considered in the analyses of the relationship between RAGE polymorphisms and cardiac outcomes.
Some limitations of our study should be considered. First, the retrospective design used to the analysis of susceptibility of HF does not allow us to rule out the possibility that there might have been a survival bias with regard to the 63-bp ins/del polymorphism. In our study, the survival analysis suggested that the African-Brazilian carriers of del allele were more likely to die. If this would be true, the lower frequency of del carriers in African-Brazilian HF patients as compared to healthy blood donors could be a consequence of the highest mortality of del carriers who have HF. It is also possible that the positive findings of the 63-bp ins/del polymorphism are due to a type 1 error, since there is almost three times more Caucasians-than African-Brazilians in our study sample. Another aspect that deserves consideration is the fact that HF patients are older than healthy blood donors. If young subjects who are prone to develop HF in the future are included in the control group, this could lead to a dilution of positive results. Moreover, we did not measure the sRAGE serum levels in our patients, and thus, we could not establish a relationship between the three RAGE gene polymorphisms and sRAGE levels. Finally, as mentioned before, HF is a multifactorial syndrome that remains a major cause of morbidity and mortality worldwide. For this reason, studies focused on the pathophysiology of this condition require a more extensive study population. Considering the small number of patients evaluated, our findings are only preliminary and require to be replicated in other studies.
In conclusion, the 63-bp ins/del, the −374T>A and the −429T>C polymorphisms in the RAGE gene were not associated with susceptibility of HF and all-cause mortality in Caucasian-Brazilian HF patients. However, among African-Brazilians, the del allele (63-bp ins/del polymorphism) was associated with a decreased risk of HF. To our knowledge, as this is the first study aimed to investigate the association of RAGE gene polymorphisms with HF, their role in the pathogenesis of HF cannot yet be elucidated. Taking into account the importance of RAGE for cardiac function and its potential use as a biomarker of prognosis in HF patients, further studies are needed to explore and clarify these associations.
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